BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLPG0634: Phase II data

Furthermore, once- and twice-daily GLPG0634 led to ACR50 response rates of 25% and 58.3%, respectively, vs. 8.3% for placebo (p=0.0591 for pooled data vs. placebo), while ACR70 response rates were 16.7% and 25%, respectively, vs. 0% for placebo (p-value not significant for pooled data vs. placebo). Galapagos said the trial was not powered to detect statistical significance. GLPG0634 was well tolerated with no severe adverse events, anemia or increases in lipids reported. The trial enrolled patients with...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >